BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17320653)

  • 1. Health perceptions in patients who undergo screening and workup for prostate cancer.
    Katz DA; Jarrard DF; McHorney CA; Hillis SL; Wiebe DA; Fryback DG
    Urology; 2007 Feb; 69(2):215-20. PubMed ID: 17320653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
    Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.
    Ankerst DP; Miyamoto R; Nair PV; Pollock BH; Thompson IM; Parekh DJ
    J Urol; 2009 May; 181(5):2071-5; discussion 2076. PubMed ID: 19286205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychological impact of serial prostate-specific antigen tests in Japanese men waiting for prostate biopsy.
    Kobayashi M; Nukui A; Kamai T
    Int J Clin Oncol; 2017 Feb; 22(1):174-180. PubMed ID: 27631094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of false-positive results for future cancer screenings.
    Taksler GB; Keating NL; Rothberg MB
    Cancer; 2018 Jun; 124(11):2390-2398. PubMed ID: 29682740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The psychological impact of prostate biopsy: Prevalence and predictors of procedure-related distress.
    Sharp L; Morgan E; Drummond FJ; Gavin A
    Psychooncology; 2018 Feb; 27(2):500-507. PubMed ID: 28766309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
    Potter SR; Horniger W; Tinzl M; Bartsch G; Partin AW
    Urology; 2001 Jun; 57(6):1100-4. PubMed ID: 11377318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
    Hoffman RM; Lo M; Clark JA; Albertsen PC; Barry MJ; Goodman M; Penson DF; Stanford JL; Stroup AM; Hamilton AS
    J Clin Oncol; 2017 Jul; 35(20):2306-2314. PubMed ID: 28493812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
    Freedland SJ; Mangold LA; Epstein JI; Partin AW
    Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year downstream outcomes following prostate-specific antigen screening in older men.
    Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
    JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
    Keetch DW; Catalona WJ; Smith DS
    J Urol; 1994 Jun; 151(6):1571-4. PubMed ID: 7514690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
    BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
    Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
    Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
    Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
    Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.